Cambridge, United Kingdom, 26th July 2023 / Domainex Ltd., a leading, integrated medicines research services partner and recent recipient of the King’s Award for Enterprise in International Trade, announces the purchase of its third, multi-channel Malvern Panalytical WAVEdelta system, powered by Creoptix technology. Simultaneously, Domainex announces the expansion of its biophysical suite of technologies through the purchase of a Malvern Panalytical PEAQ-ITC instrument with MicroCal technology.
The addition of a third WAVEdelta system to the Domainex portfolio provides the company with unsurpassed adoption of Grating-Coupled Interferometry (GCI) for the characterisation of molecular interactions. The high level of sensitivity and confidence delivered by GCI and the waveRAPID method provides increased throughput and early kinetic characterisation of the interactions between potential drug molecules and their target proteins.
GCI, a technique analogous to, but more sensitive than, surface plasmon resonance (SPR), accurately measures binding dissociation rates and kinetic parameters. The multiple WAVEdelta systems at Domainex’s Biology Centre of Excellence in Cambridge, UK, each with four channels, allow several protein targets to be assessed in parallel, significantly boosting the organisation’s capacity and turnaround time.
The Malvern Panalytical PEAQ-ITC, powered by MicroCal technology, uses the biophysical technique of Isothermal Titration Calorimetry (ITC) for the label-free study of biomolecular interactions in solution. It is a highly-sensitive instrument which requires only low sample volumes to determine affinity, stoichiometry and thermodynamic parameters for molecular interactions. The instrument provides complementary data to that delivered by GCI, broadening and consolidating Domainex’s expertise and capabilities in biophysical compound profiling.
Commenting on the purchases, Dr Tom Mander, CEO of Domainex, said: “We are seeing exceptionally strong and continuous demand for our drug discovery services from organisations across the world, the vast majority of whom provide repeat custom. We serve our clients’ needs whether it be to elucidate protein structures, support hit discovery projects or undertake fully integrated drug discovery programmes thereby optimising compounds with disease-modifying potential. Our integrated drug discovery platform provides innovation to our clients by combining our wide range of sophisticated technologies and our exceptionally talented scientists within the Cambridge UK bioscience cluster. These latest purchases will ensure we push the bar higher with cutting-edge technologies as we continue to deliver effective candidate medicines to treat a range of life-limiting human diseases.”
Dr Trevor Askwith, Head of Biology at Domainex, added: “Biophysical interactions and binding kinetics are increasingly critical for our clients’ programmes. This investment increases our capacity for delivering binding kinetics and adds the ability to measure binding thermodynamics, all in a label free solution-based system.”
Dr Mark Carnegie-Brown, VP of Pharmaceuticals at Malvern Panalytical, commented: “We are delighted to see the key role played by our WAVEdelta and PEAQ-ITC systems in Domainex’s drug discovery platform, helping accelerate the development of much-needed new medicines. As we expand our analytical portfolio and expertise upstream in the drug development workflow, we continue to build synergies with exciting companies like Domainex which provide the services needed to assess the developability of safe and effective pharmaceutical products. As demand for services and know-how to support drug discovery continues to rise, the precision, confidence and flexibility provided by three WAVEdelta systems, alongside the PEAQ-ITC, assure Domainex’s clients that their drug discovery programmes are in the best possible hands.”
For more information, contact:
Dr Tom Mander, CEO
Juliette Craggs / Maria Taylor
T: +44 (0)20 3405 7892
Notes to editors
About Domainex Ltd.
Based in Cambridge, UK and employing over 100 scientists, 95% of whom are educated to at least a Master’s degree, Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.
Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Domainex leverages its considerable knowledge of drug discovery to provide intellectual input, creativity and innovation to maximise the chance of successful identification of drug candidates to treat debilitating diseases. Domainex works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.
Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. Recently the company was proud to announce it was the recipient of a King’s Award for International Enterprise.
Full information about Domainex and its award-winning services can be found at www.domainex.co.uk.
About Malvern Panalytical
We draw on the power of our analytical instruments to make the invisible visible and the impossible possible. Through the chemical, physical and structural analysis of materials, our high-precision analytical systems support our customers in creating a better world. We help them improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy. We partner with many of the world’s biggest companies, universities and research organisations. They value us not only for the power of our solutions but also for the depth of our expertise, collaboration and integrity. We are committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. This is woven into the fabric of our business, and we help our employees and customers play their part in creating a healthier, cleaner, and more productive world. With over 2,300 employees, we serve the world, and we are part of Spectris plc, the world-leading precision measurement group.
We are Malvern Panalytical. We’re BIG on small.™
Visit www.malvernpanalytical.com for more information.